[HTML] nih.gov

[HTML][HTML] Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer

YX Li, J Le Wang, M Gao, H Tang, R Gui… - American Journal of …, 2016 - ncbi.nlm.nih.gov
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …
被引用次数：11 相关文章

Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer

YX Li, J Le Wang, M Gao, H Tang… - American journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …
[PDF] e-century.us

[PDF][PDF] Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer

YX Li, J Le Wang, M Gao, H Tang, R Gui, YF Fu - e-century.us
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …

Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.

YX Li, JL Wang, M Gao, H Tang, R Gui… - American Journal of …, 2016 - europepmc.org
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …

Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.

YX Li, JL Wang, M Gao, H Tang, R Gui… - American Journal of …, 2016 - europepmc.org
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular
due to the anticipation that it may be more effective than single drug treatment. In addition …